[Rituximab-induced acute thrombocytopenia in a patient with chronic lymphocytic leukemia]

Bobot, M; Benzaquen, M; Rouby, F; Lebowitz, Dan; Serratrice, Jacques; Durand, J-M

doi:10.1016/j.revmed.2016.08.008

Scientific article

French

[Rituximab-induced acute thrombocytopenia in a patient with chronic lymphocytic leukemia]

ContributorsBobot, M; Benzaquen, M; Rouby, F; Lebowitz, Dan; Serratrice, Jacques; Durand, J-M

Published inLa Revue de médecine interne, vol. 38, no. 5, p. 344-346

Publication date2017

Abstract

Rituximab is a chimeric anti-CD20 monoclonal antibody generally well tolerated. However, a severe but rare rituximab-related immune-toxic syndrome, associating fever, chills and thrombocytopenia can occur shortly after the infusion.

Affiliation entities

Faculté de médecine / Section de médecine clinique

Research groups

Groupe Perrier Arnaud (Médecine interne générale, de réhabilitation et de gériatrie) (585)

Citation (ISO format)

BOBOT, M et al. [Rituximab-induced acute thrombocytopenia in a patient with chronic lymphocytic leukemia]. In: La Revue de médecine interne, 2017, vol. 38, n° 5, p. 344–346. doi: 10.1016/j.revmed.2016.08.008

Article (Published version)

Identifiers

PID : unige:89803
DOI : 10.1016/j.revmed.2016.08.008
PMID : 27639907

Journal ISSN0248-8663

406views

0downloads

Creation09/11/2016 12:18:00

First validation09/11/2016 12:18:00

Update15/03/2023 01:04:27

Status update15/03/2023 01:04:26

Last indexation31/10/2024 05:22:47

Archive ouverte UNIGE

[Rituximab-induced acute thrombocytopenia in a patient with chronic lymphocytic leukemia]

Rituximab is a chimeric anti-CD20 monoclonal antibody generally well tolerated. However, a severe but rare rituximab-related immune-toxic syndrome, associating fever, chills and thrombocytopenia can occur shortly after the infusion.

Technical informations